Compare Novo Nordisk A/S (NVO) vs Tidewater Inc (TDW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Tidewater Inc — how do they compare? Novo Nordisk A/S trades at $38.63 (market cap $165.31B), while Tidewater Inc trades at $85.07 (market cap $4.21B). The key difference: Novo Nordisk A/S is far larger — about 39.3× Tidewater Inc's market cap, and Novo Nordisk A/S pays a 4.71% dividend while Tidewater Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novo Nordisk A/S for 116 Days and Tidewater Inc for 26 Days on average.
| NVO | TDW | |
|---|---|---|
Market Cap | $165.31B | $4.21B |
Volume | 11,432,838 | 590,005 |
Sector | Health | Energy |
52-Week High | $63.98 | $100.61 |
52-Week Low | $35.29 | $47.29 |
Typical Hold Time | 116 Days | 26 Days |
Enterprise Value | $179.56B | $4.25B |
Dividend Yield | 4.71% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $38.41, up 0.38% with strong fundamentals including 35.35% net margin and consistent earnings beats. The stock shows bearish technical signals but maintains robust profitability with $102.43B net income. Recent news highlights pipeline developments including Wegovy pill data and FDA reviews, while competition with Eli Lilly intensifies in the obesity drug market.
NVO presents a compelling value opportunity with a 9.66 P/E ratio and 59% upside to the $44.67 consensus target. However, technical weakness and competitive pressures from Lilly's new drug candidates pose near-term risks. The company's strong cash flow generation and 59.82% ROE support long-term growth prospects despite regulatory uncertainties.
Tidewater (TDW) trades at $85.19, up 2.15% today, with a bullish technical signal from moving averages but mixed oscillators. The company reported strong 2025 results with $1.35B revenue and $334.66M net income, though 2026 earnings have missed expectations in two quarters. Recent news includes the completion of the Wilson Sons Ultratug acquisition in August 2026, and institutional interest remains strong with BlackRock's $503.2M investment.
Outlook is cautiously optimistic with a consensus price target of $105.50, but risks include earnings volatility and competitive pressures. The stock offers potential upside from operational improvements and acquisition synergies, yet investors should monitor execution on future earnings and market conditions in the energy sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Tidewater Inc
Tidewater is the leading global provider of offshore support vessels (OSVs) to the energy industry. With the world's largest fleet of platform supply vessels (PSVs) and anchor handling tugs (AHTS), it provides critical logistics and marine support for offshore oil, gas, and renewable energy projects. Following a period of massive strategic consolidation, Tidewater is now focused on maximizing day rates and free cash flow in a supply-constrained market, positioning itself as a primary beneficiary of the multi-year offshore upcycle.
Read more on TDW →
